Climb Bio (CLYM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 5, 2026, to be held exclusively online for shareholders of record as of April 7, 2026.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Election of two Class II directors, Alexander (Bo) Cumbo and Douglas Williams, Ph.D., each for a three-year term expiring at the 2029 Annual Meeting.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Approval of an amendment to the Certificate of Incorporation regarding removal of directors for "cause."
Approval of an amendment to the 2021 Equity Incentive Plan to include prefunded warrants in the annual share pool increase calculation.
Provision for transaction of any other business that may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting FOR all director nominees and all proposals on the agenda.
Latest events from Climb Bio
- Key votes include director elections, auditor ratification, and equity plan amendment.CLYM
Proxy filing24 Apr 2026 - Annual meeting to vote on directors, auditor, and key amendments; board recommends approval.CLYM
Proxy filing10 Apr 2026 - Multiple clinical readouts in 2026 will highlight differentiated B-cell therapies and pipeline progress.CLYM
Leerink Global Healthcare Conference 20269 Mar 2026 - Multiple clinical readouts expected in 2026 for novel mAbs targeting immune-mediated diseases.CLYM
Corporate presentation5 Mar 2026 - Clinical pipeline advanced, cash runway into 2028, and key data readouts expected in 2026.CLYM
Q4 20255 Mar 2026 - Multiple clinical readouts expected in 2024 for antibody therapies in PMN, ITP, and IgAN.CLYM
Oppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026 - Five clinical readouts in 2024 and strong cash runway drive autoimmune pipeline progress.CLYM
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026 - Multiple clinical readouts expected in 2026 for novel mAbs targeting immune-mediated diseases.CLYM
Investor Presentation8 Jan 2026 - Advancing monoclonal antibodies for immune diseases, with strong clinical data and robust financial support.CLYM
Leerink Global Healthcare Conference 202526 Dec 2025